35 results
Keyword Everolimus Remove keyword
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Afinitor
everolimus, Carcinoma, Renal Cell Breast Neoplasms Pancreatic Neoplasms
Date of authorisation: 02/08/2009, Revision: 22, Authorisedreport Afinitor everolimus Procedure No.: EMEA/H/C/001038/II/0020 … Presentations: Afinitor everolimus See Annex A The following … cells11,12,13. Coadministration of everolimus and AI in breast cancer cells … -
List item
Human medicine European public assessment report (EPAR): Votubia
everolimus, Tuberous Sclerosis
Date of authorisation: 02/09/2011, Revision: 24, AuthorisedEMEA/H/C/002311 Votubia (everolimus) An overview of Votubia … contains the active substance everolimus. Tuberous sclerosis is … Votubia (Votubia (everolimus) EMA/229443/2018 Page … -
List item
Human medicine European public assessment report (EPAR): Kisplyx
lenvatinib, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016, Additional monitoring, Revision: 7, Authorisedanother cancer medicine called everolimus. Kisplyx contains the active … combination with 5 mg of everolimus once a day. The dose of Kisplyx … and the medicine containing everolimus. Kisplyx EMA/577485/2016 … -
List item
Human medicine European public assessment report (EPAR): Cabometyx
cabozantinib, Carcinoma, Renal Cell
Date of authorisation: 09/09/2016, Additional monitoring, Revision: 2, Authorisedwith the cancer medicine everolimus. Cabometyx was effective … in patients treated with everolimus. In addition, results indicated … than patients treated with everolimus (an average of 21.4 months … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma Hodgkin Disease Carcinoma, Renal Cell Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015, Additional monitoring, Revision: 21, AuthorisedOpdivo was compared with everolimus in one main study involving … months in patients given everolimus. Classical Hodgkin lymphoma … Opdivo was compared with everolimus in one main study involving … -
List item
Human medicine European public assessment report (EPAR): Voriconazole Accord
voriconazole, Aspergillosis Candidiasis Mycoses
Date of authorisation: 16/05/2013, Generic, Revision: 9, Authorised -
List item
Human medicine European public assessment report (EPAR): Voriconazole Hikma (previously Voriconazole Hospira)
voriconazole, Bacterial Infections and Mycoses Aspergillosis Candidiasis
Date of authorisation: 27/05/2015, Generic, Revision: 4, Authorised -
List item
Human medicine European public assessment report (EPAR): Ranexa (previously Latixa)
ranolazine, Angina Pectoris
Date of authorisation: 08/07/2008, Revision: 15, Authorisedciclosporin, tacrolimus, sirolimus, everolimus) may be required as RANEXA … Tacrolimus, ciclosporin, sirolimus, everolimus: Increased plasma concentrations … e.g., ciclosporin, sirolimus, everolimus). Drugs transported by … -
List item
Human medicine European public assessment report (EPAR): Emend
aprepitant, Vomiting Postoperative Nausea and Vomiting Cancer
Date of authorisation: 11/11/2003, Revision: 24, Authorisedtacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid … cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine … e.g., cyclosporine, tacrolimus, everolimus and sirolimus) is expected … -
List item
Human medicine European public assessment report (EPAR): Lutathera
lutetium (177Lu) oxodotreotide, Neuroendocrine Tumors
Date of authorisation: 26/09/2017, Additional monitoring, Revision: 1, Authorised95%CI : 8.4-13.9) in the everolimus + BSC group versus 4.6 … -
List item
Human medicine European public assessment report (EPAR): Ibrance
palbociclib, Breast Neoplasms
Date of authorisation: 09/11/2016, Additional monitoring, Revision: 5, Authorisedanastrozole may also receive everolimus (Afinitor) in combination … -
List item
Human medicine European public assessment report (EPAR): Inlyta
axitinib, Carcinoma, Renal Cell
Date of authorisation: 03/09/2012, Revision: 8, AuthorisedIFN-α, sorafenib, sunitinib, everolimus, temsirolimus, bevacizumab … -
List item
Human medicine European public assessment report (EPAR): Ivemend
fosaprepitant, Vomiting Cancer
Date of authorisation: 11/01/2008, Revision: 20, Authorisedcyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine … cyclosporine, tacrolimus, everolimus and sirolimus) is expected … -
List item
Human medicine European public assessment report (EPAR): Votrient
pazopanib, Carcinoma, Renal Cell
Date of authorisation: 14/06/2010, Revision: 20, Authorised -
List item
Human medicine European public assessment report (EPAR): Rapamune (updated)
sirolimus, Graft Rejection Kidney Transplantation
Date of authorisation: 13/03/2001, Revision: 38, Authorised -
List item
Human medicine European public assessment report (EPAR): Kisqali
ribociclib, Breast Neoplasms
Date of authorisation: 22/08/2017, Additional monitoring, Revision: 0, Authorised -
List item
Human medicine European public assessment report (EPAR): Ketoconazole HRA
ketoconazole, Cushing Syndrome
Date of authorisation: 18/11/2014, Additional monitoring, Revision: 7, Authorised -
List item
Human medicine European public assessment report (EPAR): Faslodex
fulvestrant, Breast Neoplasms
Date of authorisation: 09/03/2004, Revision: 19, Authorised -
List item
Human medicine European public assessment report (EPAR): Lojuxta
lomitapide, Hypercholesterolemia
Date of authorisation: 31/07/2013, Additional monitoring, Exceptional circumstances, Revision: 10, Authoriseddabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib … -
List item
Human medicine European public assessment report (EPAR): Xermelo
telotristat ethyl, Carcinoid Tumor Neuroendocrine Tumors
Date of authorisation: 17/09/2017, Additional monitoring, Revision: 2, Authorised -
List item
Human medicine European public assessment report (EPAR): Alecensa
alectinib, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 16/02/2017, Additional monitoring, Revision: 7, Authorised -
List item
Human medicine European public assessment report (EPAR): Zelboraf
vemurafenib, Melanoma
Date of authorisation: 17/02/2012, Revision: 18, Authoriseddabigatran etexilate, digoxin, everolimus, fexofenadine, lapatinib … -
List item
Human medicine European public assessment report (EPAR): Maviret
glecaprevir / pibrentasvir, Hepatitis C, Chronic
Date of authorisation: 26/07/2017, Additional monitoring, Revision: 3, Authorised -
List item
Human medicine European public assessment report (EPAR): Fotivda
tivozanib hydrochloride monohydrate, Carcinoma, Renal Cell
Date of authorisation: 24/08/2017, Additional monitoring, Revision: 1, Authorised -
List item
Human medicine European public assessment report (EPAR): Multaq
dronedarone, Atrial Fibrillation
Date of authorisation: 25/11/2009, Revision: 12, Authorised